Merck & Co.’s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company’s revenue, is raising investor concerns as the drug’s patent expiration approaches in 2028, The Wall Street Journal reported Feb. 5.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
